(KNSA) Kiniksa Pharmaceuticals - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 3.912m USD | Total Return: 78% in 12m
Avg Turnover: 29.6M
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 1
Warnings
Altman Z'' 0.58 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Confidence
Kiniksa Pharmaceuticals International, plc is a clinical-stage biopharmaceutical company focused on developing therapies for autoinflammatory and cardiovascular diseases. Its primary commercial product, ARCALYST, targets recurrent pericarditis and cardiac sarcoidosis by inhibiting interleukin-1alpha and 1beta cytokines. The company’s pipeline includes KPL-387, a monoclonal antibody currently in Phase 2/3 trials, and the pre-clinical candidate KPL-116.
Operating within the biotechnology sector, the company utilizes a rare disease business model, which often benefits from orphan drug designations that provide extended market exclusivity and streamlined regulatory pathways. This strategy focuses on high-unmet-need patient populations to mitigate competition from larger pharmaceutical entities. Investors can further evaluate the companys valuation metrics and pipeline milestones on ValueRay.
The firm recently underwent a corporate restructuring in June 2024, changing its legal name and domicile while maintaining its headquarters in London. This transition reflects its continued expansion from a domestic U.S. focus toward international commercialization and development operations.
- Arcalyst sales growth in recurrent pericarditis market drives core revenue expansion
- KPL-404 clinical trial data readouts determine long-term immunology pipeline valuation
- Genentech collaboration milestones and royalty payments impact cash flow stability
- Research and development expenses for early-stage pipeline assets pressure operating margins
- Market penetration and prescriber adoption of Arcalyst dictate near-term earnings performance
| Net Income: 73.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 12.60 > 1.0 |
| NWC/Revenue: 58.03% < 20% (prev 53.75%; Δ 4.28% < -1%) |
| CFO/TA 0.20 > 3% & CFO 165.9m > Net Income 73.1m |
| Net Debt (-459.1m) to EBITDA (101.5m): -4.52 < 3 |
| Current Ratio: 3.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.4m) vs 12m ago 8.23% < -2% |
| Gross Margin: 54.63% > 18% (prev 0.54%; Δ 5.41k% > 0.5%) |
| Asset Turnover: 105.9% > 50% (prev 80.28%; Δ 25.58% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.53 (Total Current Assets 594.2m - Total Current Liabilities 156.6m) / Total Assets 825.3m |
| B: -0.53 (Retained Earnings -439.5m / Total Assets 825.3m) |
| C: 0.14 (EBIT TTM 99.9m / Avg Total Assets 712.3m) |
| D: -2.00 (Book Value of Equity -440.2m / Total Liabilities 219.6m) |
| Altman-Z'' = 0.58 = B |
| DSRI: 0.37 (Receivables 23.2m/40.1m, Revenue 754.0m/481.2m) |
| GMI: 0.99 (GM 54.63% / 54.34%) |
| AQI: 0.69 (AQ_t 0.27 / AQ_t-1 0.39) |
| SGI: 1.57 (Revenue 754.0m / 481.2m) |
| TATA: -0.11 (NI 73.1m - CFO 165.9m) / TA 825.3m) |
| Beneish M = -3.44 (Cap -4..+1) = AA |
As of May 30, 2026, the stock is trading at USD 48.38 with a total of 672,577 shares traded.
Over the past week, the price has changed by -9.82%,
over one month by -8.70%,
over three months by +8.74% and
over the past year by +78.00%.
Kiniksa Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy KNSA.
- StrongBuy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 63.5 | 31.3% |
P/E Trailing = 55.8681
P/E Forward = 47.1698
P/S = 5.1874
P/B = 6.5819
Revenue TTM = 754.0m USD
EBIT TTM = 99.9m USD
EBITDA TTM = 101.5m USD
Long Term Debt = 5.86m USD (estimated: total debt 9.03m - short term 3.17m)
Short Term Debt = 3.17m USD (from shortTermDebt, last quarter)
Debt = 9.03m USD (from shortLongTermDebtTotal, last quarter) (leases 9.03m already included)
Net Debt = -459.1m USD (calculated: Debt 9.03m - CCE 468.1m)
Enterprise Value = 3.45b USD (3.91b + Debt 9.03m - CCE 468.1m)
Interest Coverage Ratio = unknown (Ebit TTM 99.9m / Interest Expense TTM 0.0)
EV/FCF = 21.02x (Enterprise Value 3.45b / FCF TTM 164.2m)
FCF Yield = 4.76% (FCF TTM 164.2m / Enterprise Value 3.45b)
FCF Margin = 21.78% (FCF TTM 164.2m / Revenue TTM 754.0m)
Net Margin = 9.69% (Net Income TTM 73.1m / Revenue TTM 754.0m)
Gross Margin = 54.63% ((Revenue TTM 754.0m - Cost of Revenue TTM 342.1m) / Revenue TTM)
Gross Margin QoQ = 55.02% (prev 54.93%)
Tobins Q-Ratio = 4.18 (Enterprise Value 3.45b / Total Assets 825.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 9.03m)
Taxrate = 30.87% (10.1m / 32.7m)
NOPAT = 69.0m (EBIT 99.9m * (1 - 30.87%))
Current Ratio = 3.79 (Total Current Assets 594.2m / Total Current Liabilities 156.6m)
Debt / Equity = 0.01 (Debt 9.03m / totalStockholderEquity, last quarter 605.7m)
Debt / EBITDA = -4.52 (Net Debt -459.1m / EBITDA 101.5m)
Debt / FCF = -2.80 (Net Debt -459.1m / FCF TTM 164.2m)
Total Stockholder Equity = 550.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.26% (Net Income 73.1m / Total Assets 825.3m)
RoE = 7.38% (Net Income TTM 73.1m / Total Stockholder Equity 990.5m)
RoCE = 10.02% (EBIT 99.9m / Capital Employed (Equity 990.5m + L.T.Debt 5.86m))
RoIC = 10.27% (NOPAT 69.0m / Invested Capital 671.8m)
WACC = 6.86% (E(3.91b)/V(3.92b) * Re(6.88%) + D(9.03m)/V(3.92b) * Rd(0.0%) * (1-Tc(0.31)))
Discount Rate = 6.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 5.76%
[DCF] Terminal Value 77.97% ; FCFF base≈116.0m ; Y1≈133.0m ; Y5≈195.8m
[DCF] Fair Price = 73.53 (EV 2.95b - Net Debt -459.1m = Equity 3.40b / Shares 46.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.73 | # QB: 0
Revenue Correlation: 98.47 | Revenue CAGR: 50.86% | SUE: 1.24 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.29 | Chg30d=+10.90% | Revisions=+0% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.32 | Chg30d=+5.39% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=1.20 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+60.0% | GrowthRev=+38.7%
EPS next Year (2027-12-31): EPS=1.76 | Chg30d=+8.35% | Revisions=+25% | GrowthEPS=+46.5% | GrowthRev=+19.9%
[Analyst] Revisions Ratio: +25%